Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks under $10 to buy now. On July 22, Taiho Oncology Inc. and Cullinan Therapeutics announced that abstracts for zipalertinib had been accepted for mini oral presentations at the International Association for the Study of Lung Cancer’s/IASLC 2025 World Conference on Lung Cancer/WCLC.

The conference is scheduled to take place from September 6-9 this year, in Barcelona, Spain. The presentations will include updated efficacy and safety data from the Phase 2b REZILIENT1 trial of zipalertinib. The trial focuses on patients with non-small cell lung cancer/NSCLC harboring epidermal growth factor receptor/EGFR exon 20 insertion mutations (ex20ins) who have been previously treated with amivantamab.

Amivantamab (sold as Rybrevant) is a bispecific monoclonal antibody that targets both EGFR and MET receptors, approved for NSCLC with EGFR ex20ins mutations. EGFR ex20ins mutations are a distinct subtype of NSCLC that are generally less responsive to conventional EGFR tyrosine kinase inhibitors (TKIs)

Cullinan Therapeutics Inc. (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases and cancer in the US.

Taiho Oncology Inc. is a company that focuses on improving the lives of cancer patients through the development and commercialization of orally administered anti-cancer agents. It is a subsidiary of Taiho Pharmaceutical Co., Ltd.

While we acknowledge the potential of CGEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.